Schizophrenia Trial, Recruiting (NCT06456983)

Schizophrenia Trial, Recruiting NCT06456983 Sponsor: Central Institute of Mental Health, Mannheim Condition: Schizophrenia

Printed from Voxsanity (voxsanity.com.au) — NCT06456983 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Schizophrenia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with schizophrenia (according to a standard medical classification system called DSM-5), have a symptom severity score above a certain level, and whose schizophrenia has not responded to a medication called clozapine — either because the medication did not work, they could not tolerate it, or it was not safe for them to take it.

Who may not be able to join:

People who have a diagnosis of dementia or significant memory and thinking problems, a current serious substance use disorder, mood disorders that include psychotic symptoms, or a personality disorder.
People who are not able to read or write in German.
People who are pregnant or currently breastfeeding.
People who have a general health condition that means it would not be safe for them to receive electroconvulsive therapy (ECT), a medical treatment involving brief electrical stimulation of the brain (confirm with trial site for details on what conditions apply).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexander Sartorius, Prof, Central Institute of Mental Health (CIMH), Mannheim, Germany

Phone: +49-621-1703

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06456983

Sponsor: Central Institute of Mental Health, Mannheim

Phase: Not Applicable

Status: Recruiting

Condition: Schizophrenia

Trial contact: +49-621-1703

More information: https://clinicaltrials.gov/study/NCT06456983

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with schizophrenia (according to a standard medical classification system called DSM-5), have a symptom severity score above a certain level, and whose schizophrenia has not responded to a medication called clozapine — either because the medication did not work, they could not tolerate it, or it was not safe for them to take it.

Who may not be able to join:

People who have a diagnosis of dementia or significant memory and thinking problems, a current serious substance use disorder, mood disorders that include psychotic symptoms, or a personality disorder.
People who are not able to read or write in German.
People who are pregnant or currently breastfeeding.
People who have a general health condition that means it would not be safe for them to receive electroconvulsive therapy (ECT), a medical treatment involving brief electrical stimulation of the brain (confirm with trial site for details on what conditions apply).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Central Institute of Mental Health, Mannheim

Registry

ClinicalTrials.gov

Start date

14 February 2025

Est. completion

1 July 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Time to relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov